World Health Organization Sounds Concern Over Critical Lack of Weight-Loss Medications
Less than 10% of individuals eligible to benefit from obesity jabs such as Wegovy have access to them, caution the global health agency as it publishes its initial advice on the drugs.
With over a billion individuals worldwide now obese, it is advocating for increased and just availability to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that obesity is a lifelong illness that can be addressed with thorough and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are significant hurdles to widespread availability to the jabs that can aid individuals in losing considerable weight, notes the organization.
Weight-Loss Drug Shortage
Even under the present best projected case, the supply of GLP-1 therapies could only cover around 100 million people – fewer than 10% of those who need them, per the health organization.
The guideline urges countries and companies to expand access, by strategies including licensing agreements.
Exclusive production rights on semaglutide – the main ingredient of a leading brand – is scheduled to end in a number of nations in 2026.
How Obesity Jabs Operate
These medications imitate a body's own hormone to slow digestion, curb appetite and increase the sense of being full so users reduce food intake.
People commonly begin shedding pounds within a few weeks of commencing the weekly injections.
Research points to people may put most of the weight back on within a year of discontinuing the drug, when their normal food cravings resume.
To be above a healthy weight increases your likelihood for experiencing diseases, such as diabetes, heart disease, stroke, and specific cancers.
Obesity concerns individuals in every country and was associated with 3.7 million fatalities worldwide in 2024, as per the WHO.
